Results 151 to 160 of about 2,123,606 (402)

Efficacy of various extent of resection on survival rates of patients with pilocytic astrocytoma: based on a large population

Scientific Reports
Pilocytic astrocytoma (PA) is classified as a Grade I benign neuroglial tumor. The extent of surgical resection is a critical factor influencing the prognosis for patients with PA.
Jun Su, Shanshan Guo, Zheyuan Chen, Yiming Han, Jingwang Yan, Qiyun Tang, Yu Mao, Haiqiang Zhang, Guojiang Hou, Gaopan Dong, Chao Guo, Pengfei Yang   +11 more
doaj   +1 more source

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. [PDF]

, 2015
BackgroundPatients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance.MethodsTumor tissue from ten patients with advanced BRAF mutation-positive melanoma who ...
Cronin, Maureen T, Falchook, Gerald, Hong, David, Hwu, Patrick, Kim, Kevin B, Kurzrock, Razelle, Stephens, Philip J, Tsimberidou, Apostolia M, Wheler, Jennifer, Yelensky, Roman   +9 more
core   +3 more sources

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Searching for targets for the systemic therapy of mesothelioma [PDF]

, 2017
Increasing knowledge about the molecular characteristics of mesothelioma had led to the identification of novel potential targets for systemic therapy. This review elaborates on the rationale behind targeted approaches that have been and are undergoing ...
Curioni-Fontecedro, A., Felley-Bosco, E., Peters, S., Petrausch, U., Schmitt-Opitz, I., Stahel, R. A., Weder, W.   +6 more
core  

Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis

Frontiers in Immunology
BackgroundCircadian rhythms in the immune system and anti-tumor responses are underexplored in cancer immunotherapy. Despite the success of immune checkpoint inhibitors (ICIs) in treating advanced biliary tract cancers (BTCs), not all patients benefit ...
Yichen Zheng, Fanfan Shi, Lingqi Sun, Jiamin Guo, Tonghui Ren, Ji Ma   +5 more
doaj   +1 more source

Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy.

World Journal of Hepatology, 2015
The incidence and mortality of hepatocellular carcinoma (HCC) have fallen dramatically in China and elsewhere over the past several decades. Nonetheless, HCC remains a major public health issue as one of the most common malignant tumors worldwide and one
Chuan Chen, Ge Wang
semanticscholar   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Structural Effects and Competition Mechanisms Targeting the Interactions between p53 and Mdm2 for Cancer Therapy [PDF]

arXiv, 2017
About half of human cancers show normal TP53 gene and aberrant overexpression of Mdm2 and/or MdmX. This fact promotes a promising cancer therapeutic strategy which targeting the interactions between p53 and Mdm2/MdmX. For developing the inhibitors to disrupt the p53-Mdm2/MdmX interactions, we systematically investigate structural and interaction ...
arxiv  

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source